JP2024543954A - Ｎａｎｔ ｃｏｖｉｄワクチン交差反応性 - Google Patents
Ｎａｎｔ ｃｏｖｉｄワクチン交差反応性 Download PDFInfo
- Publication number
- JP2024543954A JP2024543954A JP2024532354A JP2024532354A JP2024543954A JP 2024543954 A JP2024543954 A JP 2024543954A JP 2024532354 A JP2024532354 A JP 2024532354A JP 2024532354 A JP2024532354 A JP 2024532354A JP 2024543954 A JP2024543954 A JP 2024543954A
- Authority
- JP
- Japan
- Prior art keywords
- sars
- recombinant
- protein
- seq
- vaccine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163284203P | 2021-11-30 | 2021-11-30 | |
| US63/284,203 | 2021-11-30 | ||
| PCT/US2022/080561 WO2023102375A1 (en) | 2021-11-30 | 2022-11-29 | Nant covid vaccine cross reactivity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024543954A true JP2024543954A (ja) | 2024-11-26 |
| JP2024543954A5 JP2024543954A5 (https=) | 2025-06-09 |
Family
ID=86613140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024532354A Pending JP2024543954A (ja) | 2021-11-30 | 2022-11-29 | Ｎａｎｔ ｃｏｖｉｄワクチン交差反応性 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US11911459B2 (https=) |
| EP (1) | EP4440614A4 (https=) |
| JP (1) | JP2024543954A (https=) |
| KR (1) | KR20240113521A (https=) |
| CN (1) | CN118338912A (https=) |
| AU (1) | AU2022400924A1 (https=) |
| CA (1) | CA3236215A1 (https=) |
| WO (1) | WO2023102375A1 (https=) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7692925B2 (ja) * | 2020-03-11 | 2025-06-16 | ナントセル，インコーポレイテッド | Ｃｏｖｉｄ－１９の治療及びその方法 |
| EP4118225A1 (en) * | 2020-03-13 | 2023-01-18 | The Johns Hopkins University | Exosomal nucleic acid vaccine modularly configured to harness multiple antigen presentation mechanisms |
| CN115666634A (zh) * | 2020-03-27 | 2023-01-31 | 瑞典疫苗制药有限公司 | 用于治疗和预防冠状病毒的组合物和方法 |
| WO2021255270A1 (en) * | 2020-06-19 | 2021-12-23 | Ziphius Vaccines | Self-amplifying sars-cov-2 rna vaccine |
-
2022
- 2022-11-29 KR KR1020247020418A patent/KR20240113521A/ko active Pending
- 2022-11-29 WO PCT/US2022/080561 patent/WO2023102375A1/en not_active Ceased
- 2022-11-29 JP JP2024532354A patent/JP2024543954A/ja active Pending
- 2022-11-29 AU AU2022400924A patent/AU2022400924A1/en active Pending
- 2022-11-29 EP EP22902334.6A patent/EP4440614A4/en active Pending
- 2022-11-29 CN CN202280079239.5A patent/CN118338912A/zh active Pending
- 2022-11-29 CA CA3236215A patent/CA3236215A1/en active Pending
- 2022-11-30 US US18/060,513 patent/US11911459B2/en active Active
-
2023
- 2023-12-07 US US18/533,042 patent/US12016916B2/en active Active
-
2024
- 2024-03-28 US US18/620,192 patent/US12168052B2/en active Active
- 2024-09-11 US US18/882,219 patent/US20240424088A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12016916B2 (en) | 2024-06-25 |
| EP4440614A1 (en) | 2024-10-09 |
| CA3236215A1 (en) | 2023-06-08 |
| US11911459B2 (en) | 2024-02-27 |
| KR20240113521A (ko) | 2024-07-22 |
| US20240424088A1 (en) | 2024-12-26 |
| WO2023102375A1 (en) | 2023-06-08 |
| US20230190921A1 (en) | 2023-06-22 |
| EP4440614A4 (en) | 2025-12-17 |
| US20240226282A1 (en) | 2024-07-11 |
| US12168052B2 (en) | 2024-12-17 |
| CN118338912A (zh) | 2024-07-12 |
| AU2022400924A1 (en) | 2024-05-02 |
| US20240108717A1 (en) | 2024-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20220154121A (ko) | 코로나바이러스 면역원성 조성물 및 이의 용도 | |
| EA012037B1 (ru) | Поливалентные вакцины, содержащие рекомбинантные вирусные векторы | |
| WO2022003119A1 (en) | Cross-reactive coronavirus vaccine | |
| WO2022090679A1 (en) | Coronavirus polypeptide | |
| JP6917303B2 (ja) | 人工多抗原融合タンパク質およびその製造と使用 | |
| WO2023023940A1 (zh) | 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用 | |
| Ouaked et al. | Non-clinical evaluation of local and systemic immunity induced by different vaccination strategies of the candidate tuberculosis vaccine M72/AS01 | |
| WO2023160654A1 (zh) | 一种可诱导广谱中和活性重组多组分新冠病毒三聚体蛋白疫苗的制备及应用 | |
| KR101845571B1 (ko) | 전통적 돼지열에 대한 마커 백신 | |
| US20230192777A1 (en) | Epitopic vaccine for african swine fever virus | |
| US12168052B2 (en) | Nant COVID vaccine cross reactivity | |
| WO2025189435A1 (zh) | 针对猫fipv的多表位抗原构建rna疫苗的方法 | |
| CN110382518B (zh) | 用于血清型a型口蹄疫病毒的嵌合疫苗 | |
| EP4341275A1 (en) | Amino acids, nucleotides and vectors expressing the same and uses thereof in preventing sarbecovirus infection | |
| US20260053900A1 (en) | Use of virus-like particles in vaccination | |
| US20250332246A1 (en) | Enhanced expression via autotransporters | |
| US20240092840A1 (en) | Vaccine formulation comprising recombinant overlapping peptides and native proteins | |
| US20220023412A1 (en) | Compositions Useful in Both Homologous And Heterologous Vaccine Regimens | |
| CN117801119A (zh) | T细胞表位疫苗及其设计方法 | |
| WO2024152845A1 (zh) | 抗SARS-CoV-2或突变体mRNA疫苗和重组蛋白亚单位疫苗制备及应用 | |
| AU2024333842A1 (en) | T cell broad betacoronavirus vaccine | |
| WO2025189436A1 (zh) | 针对猫fipv的多表位抗原构建环状rna疫苗的方法 | |
| Pardieck et al. | an der, Gracht, ETI an der, Veerkamp, DMB, Behr, F |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250529 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250529 |